DEC 03, 2021 1:00 PM PST

FDA approves new imaging drug to make ovarian cancer tumors glow.

WRITTEN BY: J. Bryce Ortiz

Earlier this week, the United States Food and Drug Administration (FDA) announced its approval for a novel drug that can be used to make ovarian tumors glow. The drug was developed in order to assist surgeons in identifying and removing tumors and cancerous cells during surgical cancer removal. The drug was designed and developed at Purdue University and is being released for market by the biotech company On Target Labs

According to the Centers for Disease Control, ovarian cancer is the second most common gynecological cancer in the United States. Ovarian cancer occurs when cancerous cells invade the ovaries, multiply quickly, and destroy healthy tissue. Ovarian cancer is survivable if treated correctly. Treatment usually involves chemotherapy and surgery to remove the tumor and cancerous cells. However, cancer surgery can be complicated by multiple challenges that include localizing and identifying tumors and ensuring all cancerous cells have been removed. Because of these challenges, the novel drug called Cytalux was developed to mark cancer cells with a fluorescent tag that allows the cells to glow during surgery. 

The drug is delivered via an intravenous injection 1 to 9 hours prior to surgery. The drug attaches to the cancer cells which allows surgeons to easily visualize the cancer. Dr. Philip Low, a professor of chemistry at Purdue University who helped develop the drug, said that when the drug is administered and the surgeon turns on the near-infrared light, the cancer cells, “light up like stars against a night sky.” He also added, “It seems to me that future [cancer removal] surgeries are going to very heavily rely on this technology.”

The FDA-approval of the drug is based on a successful Phase 3 clinical trial that tested the drug. In the study, patients with ovarian cancer underwent surgery to remove the cancer. It was found that in 109 patients with ovarian cancer, surgeons were able to easily and accurately identify and remove the primary tumor. Importantly, the surgeons intraoperatively identified additional cancer not originally planned for resection in a statistically significant number of patients. Lastly, there were no serious drug-related adverse events. The FDA-approval of the drug is a significant milestone in cancer treatment and will help to significantly prevent ovarian cancer related deaths. 

 

Sources: FDAClinical Cancer ResearchOn Target LabsCDCJournal of Clinical Oncology

About the Author
  • Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
NOV 12, 2021
Cannabis Sciences
Battle of the Cannabinoids: Which Cannabis Compound Could Most Effectively Treat IBD?
NOV 12, 2021
Battle of the Cannabinoids: Which Cannabis Compound Could Most Effectively Treat IBD?
With 3 million people from the U.S. reporting clinical cases in 2015 – accompanied by an increased projected incid ...
NOV 18, 2021
Cannabis Sciences
Could Cannabis-Based Compounds Be the Next New Class of Antibiotics?
NOV 18, 2021
Could Cannabis-Based Compounds Be the Next New Class of Antibiotics?
According to the Centers for Disease Prevention and Control (CDC), antibiotic-resistant bacterial or fungal strains infe ...
DEC 01, 2021
Drug Discovery & Development
Researchers develop a novel drug that can combat diabetic tissue damage
DEC 01, 2021
Researchers develop a novel drug that can combat diabetic tissue damage
Diabetes is a common disease that occurs when high levels of blood sugar start to silently damage bodily tissue and orga ...
DEC 06, 2021
Microbiology
New Type of Antibiotic Targets the Bacterial Ribosome
DEC 06, 2021
New Type of Antibiotic Targets the Bacterial Ribosome
As pathogenic bacteria continue to evolve and find ways to evade common medications, researchers have been racing to dev ...
DEC 11, 2021
Health & Medicine
Third Dose of Pfizer-BioNTech Vaccine Could Reduce Effects of Omicron
DEC 11, 2021
Third Dose of Pfizer-BioNTech Vaccine Could Reduce Effects of Omicron
Many mainstream media sources are reporting on a new press release from Pfizer that suggests that a third dose of the Pf ...
DEC 27, 2021
Microbiology
Anthrax Toxin Has Potential as Non-Opioid Pain Therapeutic
DEC 27, 2021
Anthrax Toxin Has Potential as Non-Opioid Pain Therapeutic
Anthrax conjures thoughts of bioterrorism, though it's a disease caused by a rare but naturally-occurring bacterium, Bac ...
Loading Comments...